BALTIMORE--(BUSINESS WIRE)--April 5, 2006--Osiris Therapeutics, Inc. announced today that it has completed enrollment in a human clinical trial designed to evaluate the safety and preliminary effectiveness of its universal adult stem cell drug candidate Provacel(TM), being developed to treat patients suffering from heart attacks. A total of 53 patients were enrolled in the Phase I trial at ten leading heart centers across the country.
